

Cytotoxic Benzophenanthridine and Benzylisoquinoline Alkaloids from *Argemone mexicana*

Yuh-Chwen Chang^{a,b}, Fang-Rong Chang^a, Ashraf T. Khalil^a, Pei-Wen Hsieh^a, and Yang-Chang Wu^{a,*}

^a Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung 807, Taiwan. Fax: +886-7-3114773. E-mail: yachwu@kmu.edu.tw

^b Department of Chemical Engineering, Kao Yuan Institute of Technology, Kaohsiung county 821, Taiwan

* Author for correspondence and reprint requests

Z. Naturforsch. **58c**, 521–526 (2003); received January 13/February 17, 2003

Fractionation of the chloroform extract from the aerial part of *Argemone mexicana* led to the isolation of two benzophenanthridine-type alkaloids, *N*-demethyloxysanguinarine and pancorine; three benzylisoquinoline-type alkaloids, (+)-1,2,3,4-tetrahydro-1-(2-hydroxymethyl-3,4-dimethoxyphenylmethyl)-6,7-methylenedioxyisoquinoline, (+)-higenamine and (+)-reticuline. Among them, *N*-demethyloxysanguinarine is a new compound, and (+)-1,2,3,4-tetrahydro-1-(2-hydroxymethyl-3,4-dimethoxyphenylmethyl)-6,7-methylenedioxy-isoquinoline was isolated from a natural source for the first time, to which was assigned a trivial name, (+)-argenaxine. In addition, six known non-alkaloidal compounds were also isolated and identified. All compounds were characterized on the basis of their spectral data and chemical evidences. Some isolated alkaloids from this species were evaluated for their cytotoxicity to human nasopharyngeal carcinoma (HONE-1) and human gastric cancer (NUGC) cell lines. Chelerythrine was found to exhibit significant activity against NUGC cell line, while angoline inhibited both types. (+)-Argenaxine showed moderate activity against the NUGC cell line.

Key words: *Argemone mexicana*, *N*-Demethyloxysanguinarine, Cytotoxicity

Introduction

Argemone mexicana (Papaveraceae) is a spiny herbaceous annual plant that grows mainly in subtropical countries. It is widely used in folk medicine to alleviate several ailments especially for its analgesic effects (Capasso *et al.*, 1997). Chemical investigations of this plant have revealed the presence of alkaloids (Hussain *et al.*, 1983; Nakkady *et al.*, 1988), amino acids (Dinda *et al.*, 1986), phenolics (Harborne *et al.*, 1983) and fatty acids (Gunstone *et al.*, 1977). Recently, fifteen alkaloids have been isolated from the same species by our group; some with anti-HIV activity (Chang *et al.*, 2003). Our continuous search for bioactive constituents from Formosan Papaveraceae plants as well as the diverse biological activities of benzophenanthridine and benzylisoquinoline type alkaloids (Capasso *et al.*, 1997; Chang *et al.*, 2003; Krane *et al.*, 1984; Chen *et al.*, 1997; Kim *et al.*, 1999; Shin *et al.*, 1999; Tanaka *et al.*, 2001) has motivated us to continue the study of this species. In this communication, we report the isolation of two benzophenanthridine-type alkaloids, *N*-demethyloxy-

sanguinarine (**1**) and pancorine (**2**); three benzylisoquinoline-type alkaloids, (+)-argenaxine (**3**), (+)-higenamine (**4**), and (+)-reticuline (**5**). Alkaloid **1** is a new compound, and **3** was isolated for the first time from a natural source, which we named (+)-argenaxine. In addition, six known compounds were isolated and identified, *viz.* α -tocopherol (**6**), phytol (**7**), stigma-4-en-3,6-diene (**8**), adenine (**9**), adenosine (**10**), and isorhamnetin-3-O- β -D-glucopyranoside (**11**). All compounds were identified on the basis of their chemical characters and spectral data especially NMR. Some of isolated alkaloids were subjected to cytotoxic assay against human nasopharyngeal carcinoma (HONE-1) and human gastric cancer (NUGC) cell lines.

Results and Discussion

Compound **1** gave an orange color with Dragendorff's reagent indicating its alkaloidal nature and its EIMS revealed a molecular ion peak $[M]^+$ at m/z 333 corresponding to the molecular formula




Fig. 1. Structures of the isolated compounds.

$C_{19}H_{11}NO_5$. The double bond equivalence was calculated as 15. The IR spectrum of **1** showed an absorption band at 1665 cm^{-1} indicating the presence of amide carbonyl (Pandey *et al.*, 1979). The ^1H NMR showed six aromatic protons and two methylenedioxy groups at δ 6.11 and 6.30 (each 2H, s), suggesting the presence of benzophenanthridine nucleus (Krane *et al.*, 1984). The NOESY spectrum (Fig. 2) showed two peaks between δ 7.14 (1H, s, H-4) and δ 7.55 (1H, d, $J = 8.8$ Hz, H-5) and between δ 7.65 (1H, d, $J = 8.8$ Hz, H-12) and δ 7.82 (1H, d, $J = 8.8$ Hz, H-6), indicating that the two methylenedioxy groups were attached to C-2/C-3 and C-9/C-10. Comparing the NMR data of **1** with those of oxyanguinarine (Williams *et al.*, 1993), it was found that they are similar except for




Fig. 2. NOESY cross-peaks observed for compound **2**.

the disappearance of the signal attributed to *N*-methyl group. Based on the results mentioned above, it was concluded that **1** is *N*-demethoxyanguinarine.

The EIMS of **3** revealed a $[\text{M}-\text{H}_2\text{O}]^+$ ion at m/z 339 corresponding to the molecular formula

$C_{20}H_{23}NO_5$, and the UV absorption at 225 and 285 nm, suggesting the presence of an aromatic alkaloid with an attached alcoholic group. In the aromatic region, the 1H NMR showed an AB pattern at δ 6.95 (1H, d, $J = 8.5$ Hz, H-5') and δ 7.03 (1H, d, $J = 8.5$ Hz, H-6'), and two aromatic proton singlets at δ 6.76 (H-5) and 6.82 (H-8). The spectral data of **3** suggested the presence of a benzylisoquinoline nucleus with a methylenedioxy group as indicated by a signal at δ 5.93 (2H, s) and two methoxyl groups as evidenced from the two singlets at δ 3.82 and 3.86 (each 3H, s). The methylenedioxy group was most likely located on the aromatic ring at positions C-6 and C-7, thus allowing H-5 and H-8 to be *para*-located. The presence of hydroxymethyl group was deduced from the two spin-coupled doublets at δ 4.86, 4.79 (each d, $J = 11.5$ Hz, CH_2OH). All spectral data of **3** were consistent with the reported values (Hanaoka *et al.*, 1983). The above data confirmed that **3** has the structure of 1,2,3,4-tetrahydro-1-(2-hydroxy-methyl-3,4-dimethoxyphenyl-methyl)-6,7-methylenedioxyisoquinoline. Although **3** was previously synthesized (Hanaoka *et al.*, 1983), this is the first detection of this alkaloid in a natural source. We named it (+)-argenaxine. It could be an intermediate in the biogenesis pathway of protoberberine-type alkaloids.

Furthermore, alkaloids **2** (Krane *et al.*, 1984), **4** (Xu and Lin, 1999), **5** (Shamma *et al.*, 1983; Castro *et al.*, 1985), **6** (Mozawa *et al.*, 2000), **7** (Bjornland *et al.*, 1989), **8** (Itokawa *et al.*, 1973), **9** (Kawahara *et al.*, 1992), **10** (Chen *et al.*, 1997), and **11** (Harborne and Mabry, 1982) were identified by direct comparison of their physical and spectral data with the literature values.

Moreover, some isolated alkaloids of our current and previous (Chang *et al.*, 2003) investigation were evaluated for their cytotoxicity to human nasopharyngeal carcinoma (HONE-1) and human gastric cancer (NUGC) cell lines (Table I). Alkaloid **12** was found to be active against NUGC cell line, while **13** inhibited both types. Alkaloid **3** showed moderate activity against NUGC cell line.

Experimental

General experimental procedures for instrumentation, plant information, source of alkaloids, and preliminary fractionation, see Chang *et al.* (2003).

Table I. Cytotoxicity of the alkaloids isolated from *Argemone mexicana*.

Sample (150 μ M)	% of control	
	HONE-1	NUGC
<i>N</i> -Demethyloxysanguinarine (1)	91	104
Pancorine (2)	96	100
(+)-Argenaxine	92	64
(+)-Higenamine (4)	95	97
(+)-Reticuline (5)	96	90
Chelerythrine (12)	109	1
Angoline (13)	1	0
<i>O</i> -Methylzanthoxyline	–	95
Norchelerythrine	–	86
Sanguinarine	–	100
6-Acetyldihydrosanguinarine	–	105
6-Acetyldihydrochelerythrine	–	98
Aronttianamide	–	93
Berberine	–	128
Dihydrocheilantifoline	–	128

– Not tested.

Extraction and isolation

The air-dried whole plants (1.5 kg) of *A. mexicana* were extracted repeatedly with MeOH (201 \times 5) at room temperature, and concentrated *in vacuo* to yield a dark residue (310 g). The MeOH extract showed cytotoxic activity. The residue was dissolved in H_2O –MeOH (5:1 v/v) mixture (1.5 l) then successively extracted with $CHCl_3$ (1.5 l \times 3) and then with *n*-BuOH (1.5 l \times 3) till exhaustion. Each extract was separately concentrated *in vacuo* to yield $CHCl_3$ (48.3 g) and *n*-BuOH (14.7 g) residues. The $CHCl_3$ extract was subjected to column chromatography on Si gel with a gradient solvent system of *n*-hexane– $CHCl_3$ –MeOH to give **1** (3 mg, $CHCl_3/MeOH$ [50:1 v/v], R_f 0.44), **2** (4.5 mg, $CHCl_3/MeOH$ [50:1], R_f 0.49), **3** (12 mg, $CHCl_3/MeOH$ [8:1], R_f 0.43), **6** (25 mg, *n*-hexane/ $CHCl_3$ [5:1], R_f 0.55), **7** (35 mg, *n*-hexane/ $CHCl_3$ [5:1], R_f 0.50), and **8** (15 mg, $CHCl_3/MeOH$ [99:1], R_f 0.65). The *n*-BuOH extract was subjected to column chromatography on silica gel with a gradient system of $CHCl_3$ –EtOAc–MeOH to produce eleven fractions. Fraction No. 9 was re-chromatographed on Si gel column using $CHCl_3/MeOH$ for gradient elution followed by purification on Sephadex LH-20 using MeOH/ $CHCl_3$ as a solvent to afford **4** (15 mg, $CHCl_3/MeOH$ [10:1 v/v], R_f 0.42), **5** (9 mg, $CHCl_3/MeOH$ [10:1], R_f 0.52). Fractions No. 6–8 were repeatedly chromatographed on Si gel column

using $\text{CHCl}_3/\text{MeOH}$ for gradient elution followed by purification on preparative TLC using $\text{CHCl}_3/\text{MeOH}$ [10:1] to offer **9** (25 mg, $\text{CHCl}_3/\text{MeOH}$ [10:1 v/v], R_f 0.56), **10** (35 mg, $\text{CHCl}_3/\text{MeOH}$ [10:1], R_f 0.49) and **11** (15 mg, $\text{CHCl}_3/\text{MeOH}$ [10:1], R_f 0.46).

N-Demethyloxysanguinarine or 2,3-methylenedioxy-9,10-methylenedioxy-benzo[*c*]phenanthridin-8-one (**1**)

White amorphous powder, UV (EtOH), λ_{max} (log ϵ), 222 (4.02), 283 (3.36), and 327 (4.13) nm. IR (KBr) ν_{max} , 1665 (carbonyl group), 943, 1032 (methylenedioxy group) cm^{-1} . $^1\text{H-NMR}$ (400 MHz, CDCl_3), δ 6.11 (2H, s, $\text{C}_{2\&3}-\text{OCH}_2\text{O}-$), 6.30 (2H, s, $\text{C}_{9\&10}-\text{OCH}_2\text{O}-$), 7.14 (1H, s, H-4), 7.29 (1H, d, $J = 8.8$ Hz, H-11), 7.55 (1H, d, $J = 8.8$ Hz, H-5), 7.65 (1H, d, $J = 8.8$ Hz, H-12), 7.82 (1H, d, $J = 8.8$ Hz, H-6), 7.86 (1H, s, H-1); EI-MS, m/z (rel. int. %) : 333 (57) $[\text{M}]^+$, 322 (13), 248 (10), 161 (21), 69 (70), 55 (100), $\text{C}_{19}\text{H}_{11}\text{NO}_5$.

Pancorine (**2**)

White amorphous powder, UV (EtOH) λ_{max} (log ϵ), 220 (3.85), 278 (3.36), and 325 (4.08) nm; IR (KBr) ν_{max} , 940, 1035 (methylenedioxy group) cm^{-1} . $^1\text{H-NMR}$ (400 MHz, CDCl_3), δ 3.91 (3H, s, C_8-OCH_3), 6.10 (2H, s, $\text{C}_{2\&3}-\text{OCH}_2\text{O}-$), 6.27 (2H, s, $\text{C}_{9\&10}-\text{OCH}_2\text{O}-$), 7.16 (1H, s, H-4), 7.25 (1H, d, $J = 8.8$ Hz, H-11), 7.52 (1H, d, $J = 8.8$ Hz, H-5), 7.57 (1H, s, H-1), 7.76 (1H, d, $J = 8.8$ Hz, H-12), 7.98 (1H, d, $J = 8.8$ Hz, H-6); EI-MS, m/z : 347 $[\text{M}]^+$, $\text{C}_{20}\text{H}_{13}\text{NO}_5$.

(+)-Argenaxine or 1,2,3,4-tetrahydro-1-(2-hydroxy-methyl-3,4-dimethoxy-phenylmethyl)-6,7-methylenedioxyisoquinoline (**3**)

Colorless prisms; m.p. 157–158 °C; $[\alpha]_{\text{D}}^{24} +95^\circ$ (c 0.34, CHCl_3). UV (MeOH) λ_{max} (log ϵ), 225 (4.14), 285 (3.38) nm. IR (KBr) ν_{max} , 3381 (OH), 1620, 970 cm^{-1} . $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 3.28 (2H, m, H-4), 3.31 (2H, m, CH_2-C_1), 3.48 (1H, m, H-3a), 3.70 (1H, m, H-3b), 3.82, 3.86 (each 3H, s, OCH_3 X 2), 3.94 (1H, m, H-1), 4.86, 4.79 (each d, $J = 11.5$ Hz, CH_2OH), 5.93 (2H, s, $\text{C}_{6\&7}-\text{OCH}_2\text{O}-$), 6.76 (1H, s, H-5), 6.82 (1H, s, H-8), 6.95 (1H, d,

$J = 8.5$ Hz, H-5'), 7.03 (1H, d, $J = 8.5$ Hz, H-6'); EI-MS, m/z (rel. int. %): 357 $[\text{M}]^+$ (2), 339 $[\text{M}-\text{H}_2\text{O}]^+$ (42), $\text{C}_{20}\text{H}_{23}\text{NO}_5$.

(+)-Higenamine (**4**)

Colorless amorphous powder, m.p. 255–256 °C; $[\alpha]_{\text{D}}^{24} +85^\circ$ (c 0.74, CHCl_3), UV λ_{max} (MeOH) nm (log ϵ), 225 (4.52), 285 (4.53). IR (KBr) ν_{max} cm^{-1} , 3400 (OH), 1613, 945 cm^{-1} . $^1\text{H-NMR}$ (400 MHz, CDCl_3), δ 3.02 (2H, m, CH_2-C_1), 3.26 (2H, m, H-4a&H-4b), 3.35 (1H, m, H-3a), 3.44 (1H, m, H-3b), 4.58 (1H, br.s, H-1), 6.62 (1H, s, H-5), 6.63 (1H, s, H-8), 6.81 (2H, d, $J = 8.0$ Hz, H-3'&H-5'), 7.15 (2H, d, $J = 8.0$ Hz, H-2'&H-6'); EI-MS, m/z (rel. int. %): 271 $[\text{M}]^+$ (4), 164 (100), 149 (18), 107 (34), 77 (29), $\text{C}_{16}\text{H}_{17}\text{NO}_3$.

(+)-Reticuline (**5**)

White needles, m.p. 200–202 °C; $[\alpha]_{\text{D}}^{24} +112^\circ$ (c 0.22, CHCl_3). UV λ_{max} (MeOH) nm (log ϵ), 258 (4.50), 285 (4.39), 334 (2.17). IR (KBr) ν_{max} , 3400, 1608, 940 cm^{-1} . $^1\text{H-NMR}$ (400 MHz, CDCl_3): δ 2.50 (3H, s, $\text{N}-\text{CH}_3$), 2.65 (1H, dd, $J = 13.8$, 4.6 Hz, CH_2-C_1), 2.76 (1H, dd, $J = 13.8$, 6.8 Hz, CH_2-C_1), 2.81 (2H, m, H-4a & H-4b), 3.10 (1H, m, H-3a), 3.17 (1H, m, H-3b), 3.74 (1H, t, $J = 6.8$ Hz, H-1), 3.82 & 3.84 (each 3H, s, OCH_3 X 2), 6.27 (1H, s, H-5), 6.50 (1H, s, H-8), 6.54 (1H, d, $J = 8.4$ Hz, H-5'), 6.71 (1H, dd, $J = 8.4$, 2.4 Hz, H-6'), 6.77 (1H, d, $J = 2.4$ Hz, H-2'). EI-MS, m/z (rel. int. %): 329 (52) $[\text{M}]^+$ (5), 192 (100), 177 (5), 105 (18), 57 (61), 43 (78), $\text{C}_{19}\text{H}_{23}\text{NO}_4$.

α -Tocopherol (**6**)

Yellowish oil, UV λ_{max} (EtOH) nm (log ϵ), 295 (4.05). IR (Nujol) ν_{max} , 3450, 2960, 2875, 1030 cm^{-1} . $^1\text{H-NMR}$ (200 MHz, CDCl_3), δ 0.85 (12H, m, $\text{CH}_3-4'a, 8'a, 12'a, 13'$), 1.05–1.62 (19 H, m, H-2', 3', 4', 5', 6', 7', 8', 9', 10', 11', 12'), 1.80 (2H, m, H-3), 2.11 (6H, s, CH_3-5 & CH_3-7), 2.16 (8H, m, H-4, CH_3-8 , CH_3-2a), 2.61 (2H, t, $J = 6.7$ Hz, H-1'), 4.20 (1H, br.s., OH-6). EI-MS, m/z (rel. int. %): 430 $[\text{M}]^+$ (53), 207 (26), 165 (74), 95 (35), 83 (32), 81 (51), 57 (62), 55 (73), 43 (100), $\text{C}_{29}\text{H}_{50}\text{O}_2$.

trans-Phytol or (2*E*)-3,7,11,15-tetramethyl-2-hexadecen-1-ol (7)

Colorless oil, UV λ_{\max} (EtOH) nm (log ϵ), 210 (3.99), 235 (4.22). IR (Neat) ν_{\max} , 3500, 2980, 1650, 1590 cm^{-1} . $^1\text{H-NMR}$ (200 MHz, CDCl_3): δ 0.84 (6H, dd, $J = 6.8, 1.6$ Hz, CH_3 -18, 19), 0.88 (6H, d, $J = 6.0$ Hz, CH_3 -16, 20), 1.10–1.50 (20H, m), 1.66 (3H, s, CH_3 -17), 1.99 (2H, br.t, $J = 7.2$ Hz, H-4), 4.15 (2H, d, $J = 7.0$ Hz, H-1), 5.39 (1H, br.t, $J = 7.0, 1.2$ Hz, H-2). $^{13}\text{C-NMR}$ (50 MHz, CDCl_3): δ 16.0 (C-17), 19.6 (C-18,19), 22.6 (C-16,20), 24.4 (C-9), 24.7 (C-13), 25.1 (C-5), 27.9 (C-15), 32.6 (C-7), 32.7 (C-11), 36.6 (C-6), 37.2 (C-12), 37.3 (C-8,10), 39.3 (C-14), 39.8 (C-4), 59.0 (C-1), 123.3 (C-2), 139.4 (C-3); EI-MS, m/z (rel. int. %): 296 $[\text{M}]^+$ (3), 279 (17), 149 (100).

Stigma-4-en-3,6-dione (8)

Colorless needles (CHCl_3), m.p. 137–139 °C; $[\alpha]_{\text{D}}^{24} -38^\circ$ (c 0.1, CHCl_3), UV λ_{\max} (EtOH) nm (log ϵ), 255 (4.38), 322 (3.25). IR (KBr) ν_{\max} , 1685 (conj. C=O), 1610 cm^{-1} . $^1\text{H-NMR}$ (400 MHz, CDCl_3): δ 0.72 (3H, s, H-18), 0.81 (3H, d, $J = 6.4$ Hz, H-26), 0.82 (1H, m, H-24), 0.83 (3H, d, $J = 6.1$ Hz, H-27), 0.85 (3H, t, $J = 6.9$ Hz, H-29), 0.95 (3H, d, $J = 6.5$ Hz, H-21), 1.16 (3H, s, H-19), 1.10–1.59 (11H, m, H-11, 12a, 14, 15a, 16a, 17, 20, 22), 1.85–1.95 (3H, m, H-1a&8&16b), 2.00–2.20 (6H, m, H-23&7a&12b&28), 2.30 (1H, m, H-1b), 2.46 (1H, m, H-2a), 2.58 (1H, m, H-2b), 2.68 (1H, dd, $J = 15.6, 3.8$ Hz, H-7b), 6.17 (1H, s, H-4). $^{13}\text{C-NMR}$ (100 MHz, CDCl_3): δ 11.7 (C-29), 11.9 (C-18), 17.3 (C-19), 18.5 (C-21), 18.6 (C-27), 19.2 (C-26), 20.7 (C-11), 22.9 (C-28), 23.8 (C-15), 25.8 (C-23), 27.8 (C-16), 28.9 (C-25), 33.6 (C-22), 33.7 (C-2), 33.9 (C-10), 35.3 (C-20), 35.8 (C-1), 38.9 (C-8), 39.6 (C-12), 42.3 (C-13), 45.6 (C-24), 46.5 (C-7), 50.7 (C-9), 55.5 (C-14), 56.4 (C-17), 125.2 (C-4), 160.8 (C-5), 199.2 (C-3), 201.9 (C-6); EI-MS, m/z (rel. int. %): 426 $[\text{M}]^+$ (20), 411 $[\text{M}-\text{CH}_3]^+$ (5), 408 $[\text{M}-\text{H}_2\text{O}]^+$ (10), 398 (18), 384 (9), 285 (18), 243 (37), 137 (100), 109 (41), 91 (43), 81 (75), 69 (98), $\text{C}_{29}\text{H}_{46}\text{O}_2$.

Adenine (9)

Colorless needles (MeOH), m.p. 173–174 °C; orange color with Dragendorff's reagent. UV λ_{\max} (MeOH) nm, 260, 295, 323, 346. IR (KBr) ν_{\max} , 3380 (N–H st.), 3200 (C=C st) cm^{-1} . $^1\text{H-NMR}$

(200 MHz, CD_3OD), δ 8.13 (1H, s, H-2), 8.20 (1H, s, H-8). EI-MS, m/z : 135 $[\text{M}]^+$, 119 $[\text{M}-\text{NH}_2]^+$, $\text{C}_5\text{H}_5\text{N}_5$.

Adenosine (10)

Colorless needles (MeOH), m.p. 196–198 °C; orange color with Dragendorff's reagent. UV λ_{\max} (MeOH) nm (log ϵ), 220 (4.48), 253 (4.39). IR (KBr) ν_{\max} , 3480 (O–H st), 3120 (C=C st), 1600, 1495 cm^{-1} . $^1\text{H-NMR}$ (200 MHz, CD_3OD), δ 3.60–5.14 (5H, m, H-2',3',4',5'), 5.96 (1H, d, $J = 6.4$ Hz, H-1'), 8.18 (1H, s, H-2), 8.30 (1H, s, H-8); EI-MS, m/z (rel. int. %): 267 $[\text{M}]^+$ (53), 237 (32), 178 (18), 164(38), 148 (39), 135 (21), $\text{C}_{10}\text{H}_{13}\text{N}_5\text{O}_4$.

Isorhamnetin 3-O- β -glucopyranoside (11)

Yellow needles (MeOH), m.p.: 278–280 °C; $[\alpha]_{\text{D}}^{24} -85^\circ$ (c 0.5, CHCl_3). UV λ_{\max} (EtOH) nm (log ϵ), 252 (4.67), 298 (4.13), 377 (4.55). IR (KBr) ν_{\max} , 3300 (OH), 1650 (conj.C=O), 1600 cm^{-1} . $^1\text{H-NMR}$ (400 MHz, CD_3OD), δ 3.24 (1H, m, H-3''), 3.45 (1H, m, H-4''), 3.47 (1H, m, H-5''), 3.57 (1H, m, H-2''), 3.74 (1H, dd, $J = 12.0; 2.4$ Hz, Ha-6''), 3.65 (1H, dd, $J = 12.0; 5.5$ Hz, Hb-6''), 3.94 (3H, s, $\text{C}_3'-\text{OCH}_3$), 5.40 (1H, d, $J = 7.6$ Hz, H-1''), 6.19 (1H, d, $J = 2.0$ Hz, H-6), 6.28 (1H, d, $J = 2.0$ Hz, H-8), 6.90 (1H, d, $J = 8.6$ Hz, H-5'), 7.58 (1H, d, $J = 2.0$ Hz, H-2'), 7.92 (1H, dd, $J = 8.6; 2.0$ Hz, H-6'). $^{13}\text{C-NMR}$ (50 MHz, CD_3OD), δ 58.8 ($\text{C}_3'-\text{OCH}_3$), 62.6 (C-6''), 71.5 (C-4''), 75.9 (C-2''), 78.1 (C-5''), 78.5 (C-3''), 94.7 (C-8), 99.9 (C-6), 103.6 (C-1''), 104.2 (C-10), 114.4 (C-2'), 116.0 (C-5'), 123.1 (C-1'), 123.9 (C-6'), 135.3 (C-3), 148.4 (C-4'), 150.8 (C-3'), 158.4 (C-2), 158.9 (C-3), 163.0 (C-9), 165.9 (C-7), 179.4 (C-4). EI-MS, m/z (rel. int. %): 316 (100) $[\text{M}-\text{glucosyl}]^+$, 301 (8), 287 (12), $\text{C}_{22}\text{H}_{22}\text{O}_{12}$.

Biological assays

The compounds isolated from *A. mexicana* were tested against two human cancer cell lines, Hone-1 (nasopharyngeal carcinoma) and NUGC (human gastric cancer cells) [The cell lines were deposited in the National Health Research Institute, Taipei, Taiwan, with deposit no. 60259 and 60621, respectively]. Cell lines were maintained in Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% fetal calf serum (Gibco). Cultures were established in 96-well plates for 24 h. After a 72-h

exposure to the test compounds (50 µg/ml each), the percentage of cell viability was determined using the MTS [3-(4,5-methylthiazol-2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfonyl)-2H-tetrazolium, inner salt] colorimetric assay. Actinomycin D (100% ~ 98% inhibition at the concentration of 50 µg/ml) was used as a positive control, according to a previously described procedure (Malich *et al.*, 1997)

Acknowledgements

This work was supported in part by funding from the National Science Council (NSC) and National Health Research Institute (NHRI) of the Republic of China.

- Bjornland T., Lianen-Jensen S., and Thronsen J. (1989), Carotenoids of the marine chrysophyte *Pelagococcus subviridis*. *Phytochemistry* **28**, 3347–3353.
- Capasso A., Piacente S., Pizza C., Tommasi N. D., Jativa C., and Sorrentino L. (1997), Isoquinoline alkaloids from *Argemone mexicana* reduce morphine withdrawal in guinea pig isolated ileum. *Planta Med.* **63**, 326–28.
- Castro O. C., Lopez J. V., and Vergara A. G. (1985), Aporphine alkaloids from *Phoebe pittieri*. *Phytochemistry* **24**, 203–204.
- Chang Y.C., Hsieh P. W., Chang F. R., Wu R. R., Liaw C. C., Lee K. H., and Wu Y. C. (2003), New protopine and the anti-HIV alkaloid 6-acetyl-dihydrochelerythrine from Formosan *Argemone mexicana*. *Planta Med.* **69**, 148–152.
- Chen C. Y., Chang F. R., and Wu Y. C. (1997), The constituents from the stems of *Annona cherimola*. *J. Chin. Chem. Soc.* **44**, 313–319.
- Chen I. S., Chen J. J., Duh C. Y., Tsai I. L., and Chang C. T. (1997), New aporphine alkaloids and cytotoxic constituents of *Hernandia nymphaeifolia*. *Planta Med.* **63**, 154–157.
- Dinda B., and Bandyopadhyay M. J. (1986), Free amino acids of *Argemone mexicana*. *J. Indian. Chem. Soc.* **63**, 934–36.
- Gunstone F. D., Holliday J. A., and Scrimgeour C. M. (1977), Fatty acids, Part 51. The long-chain oxoacids (argemonic acids) in *Argemone mexicana* seed oil. *Chem. Phys. Lipids* **20**, 331–335.
- Hanaoka M., Nagami K., Inoue M., and Yasuda S. (1983), Chemical transformation of Protoberberines. IV. A novel, simple synthesis of (±)-canadoline and a retroprotoberberine from tetrahydroberberine. *Chem. Pharm. Bull.* **31**, 2685–90.
- Harborne J. B. and Mabry T. J. (1982), *The Flavonoids: Advances in Research*. Chapman and Hall, London.
- Harborne J. B. and Williams C. A. (1983), Flavonoids in the seeds of *Argemone mexicana*: a reappraisal. *Phytochemistry* **22**, 1520–1521.
- Hussain S. F., Nakkady S., Khan L., and Shamma M. (1983), oxyhydrastinine, an isoquinoline alkaloid from the Papaveraceae. *Phytochemistry* **22**, 319–320.
- Itokawa H., Akasu M., and Fujita M. (1973), Several oxidized sterols isolated from callus tissue of *Stephania cepharantha*. *Chem. Pharm. Bull.* **21**, 1386–1387.
- Kawahara N., Sekita S., Satake M., and Udagawa S. I. (1992), A nucleoside derivative from *Emericellia nidulans*. *Phytochemistry* **31**, 1409–1410.
- Kim S. R., Hwang S. Y., Jang Y. P., Park M. J., Markelonis G. J., Oh T. H., and Kim Y. C. (1999), Protopine from *Corydalis ternate* has anticholinesterase and anti-amnesic activities. *Planta Med.* **65**, 218–21.
- Krane B. D., Fagbule M. O., Shamma M., and Gozler B. (1984), The benzophenanthridine alkaloids. *J. Nat. Prod.* **47**, 1–43.
- Malich G., Markovic B., and Winder C. (1997), The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. *Toxicology* **124**, 179–192.
- Mozawa M., Takahashi K., Kato K., and Akita H. (2000), Enantioselective synthesis of (2*R*,4'*R*,8'*R*)- α -tocopherol (vitamin E) based on enzymatic function. *Chem. Pharm. Bull.* **48**, 272–277.
- Nakkady S. and Shamma, M. (1988), Studies on the chemical constituents of *Argemone mexicana*. *Egypt. J. Pharm. Sci.* **29**, 53–61.
- Pandey V. B., Ray A. B., and Dasgupta B. (1979), Minor alkaloids of *Fumaria indica* seeds. *Phytochemistry* **18**, 695–696.
- Shamma M., Minard R. D., Freyer A. J., and Guinaudeau H. (1983), Novel biogenetic pathways from (+)-reticuline. Three dimeric alkaloids: (+)-vanuatine, (+)-vateamine, and (+)-Malekulatine. *J. Org. Chem.* **48**, 3957–3960.
- Shin J. S., Yun-Choi H. S., Kim E. I., and Lee M. K. (1999), Inhibitory effects of higenamine on dopamine content in PC12 cells. *Planta Med.* **65**, 452–455.
- Tanaka S., Sakata Y., Morimoto K., Tambe Y., Watanabe Y., Honda G., Tabata M., Oshima T., Masuda T., Umezawa T., Shimada M., Nagakura N., Kamisako W., Kashiwada Y., and Ikeshiro T. (2001), Influence of natural and synthetic compounds on cell surface expression of cell adhesion molecules, ICAM-1 and VCAM-1. *Planta Med.* **67**, 108–113.
- Williams R. D. and Ellis B. E. (1993), Alkaloids from *Agrobacterium rhizogenes*-transformed *Papaver somniferum* cultures. *Phytochemistry* **32**, 719–723.
- Xu Q. and Lin M. (1999), Benzylisoquinoline alkaloids from *Gnetum parvifolium*. *J. Nat. Prod.* **62**, 1025–1027.